

Wen-Wu Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2850662/publications.pdf>

Version: 2024-02-01

42
papers

1,465
citations

516215

16
h-index

329751

37
g-index

45
all docs

45
docs citations

45
times ranked

2769
citing authors

#	ARTICLE	IF	CITATIONS
1	The relationship between myopia progression and axial elongation in children wearing orthokeratology contact lenses. <i>Contact Lens and Anterior Eye</i> , 2023, 46, 101517.	0.8	5
2	FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	1.4	9
3	Change in Corneal Power Distribution in Orthokeratology: A Predictor for the Change in Axial Length. <i>Translational Vision Science and Technology</i> , 2022, 11, 18.	1.1	13
4	Long-term follow-up for monovision surgery by Implantable Collamer Lens V4c implantation for myopia correction in early presbyopia. <i>Graefé's Archive for Clinical and Experimental Ophthalmology</i> , 2022, , 1.	1.0	4
5	XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-label, multicenter, randomized, prospective phase III trial (EXELOX). <i>Cancer Communications</i> , 2022, 42, 314-326.	3.7	13
6	The Effect of Lens Design on Corneal Power Distribution in Orthokeratology. <i>Optometry and Vision Science</i> , 2022, 99, 363-371.	0.6	13
7	A Comprehensive Investigation of Contrast Sensitivity and Disk Halo in High Myopia Treated With SMILE and EVO Implantable Collamer Lens Implantation. <i>Translational Vision Science and Technology</i> , 2022, 11, 23.	1.1	7
8	Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β -catenin/SIX1 signaling pathway in gastric cancer. <i>Cell Biology and Toxicology</i> , 2021, 37, 35-49.	2.4	6
9	A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 513-521.	0.7	4
10	Chemotherapy and targeted therapy near the end of life affects aggressiveness of palliative care. <i>Annals of Palliative Medicine</i> , 2021, 10, 2917-2925.	0.5	3
11	Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, Tj ETQq1 1 0.784314 rgBT /Ove Journal of Clinical Oncology, 2021, 39, 4014-4014.	0.8	2
12	ALKBH5-mediated m6A demethylation of lncRNA RMRP plays an oncogenic role in lung adenocarcinoma. <i>Mammalian Genome</i> , 2021, 32, 195-203.	1.0	29
13	Cation Lipid-Assisted PEG6-PLGA Polymer Nanoparticles Encapsulated Knocking Down Long ncRNAs Reverse Non-Coding RNA of Xist Through the Support Vector Machine Model to Regulate the Molecular Mechanisms of Gastric Cancer Cell Apoptosis. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 1305-1319.	0.5	10
14	Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma. <i>Neoplasia</i> , 2021, 23, 870-878.	2.3	3
15	Safety of EVO ICL Implantation With an Ophthalmic Viscosurgical Device-Free Technique in the Early 24 h After Surgery. <i>Frontiers in Medicine</i> , 2021, 8, 764653.	1.2	5
16	Use of palliative chemotherapy near the end of life: a retrospective cohort study. <i>Annals of Palliative Medicine</i> , 2020, 9, 2809-2816.	0.5	3
17	A validated LC-MS/MS method for the quantification of capivasertib in dog plasma: Application to its pharmacokinetics study. <i>Biomedical Chromatography</i> , 2020, 34, e4920.	0.8	0
18	Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 679-690.	2.1	38

#	ARTICLE	IF	CITATIONS
19	Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4054-4054.	0.8	2
20	Palliative Chemotherapy Near the End of Life in Oncology Patients. <i>American Journal of Hospice and Palliative Medicine</i> , 2018, 35, 1215-1220.	0.8	14
21	Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells. <i>Oncology Letters</i> , 2018, 16, 5983-5991.	0.8	5
22	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). <i>Liver Cancer</i> , 2018, 7, 235-260.	4.2	426
23	Use of Palliative Chemo- and Radiotherapy at the End of Life in Patients With Cancer: A Retrospective Cohort Study. <i>American Journal of Hospice and Palliative Medicine</i> , 2017, 34, 801-805.	0.8	13
24	Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. <i>International Journal of Cancer</i> , 2017, 141, 2093-2102.	2.3	12
25	Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer. <i>Oncotarget</i> , 2017, 8, 40765-40777.	0.8	55
26	Timing of referral to inpatient palliative care services for advanced cancer patients and earlier referral predictors in mainland China. <i>Palliative and Supportive Care</i> , 2016, 14, 503-509.	0.6	14
27	Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. <i>Oncotarget</i> , 2016, 7, 10332-10344.	0.8	50
28	MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer. <i>Oncotarget</i> , 2015, 6, 25418-25428.	0.8	56
29	Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. <i>Oncotarget</i> , 2015, 6, 40519-40534.	0.8	16
30	Cultural and Ethical Considerations for Cardiopulmonary Resuscitation in Chinese Patients With Cancer at the End of Life. <i>American Journal of Hospice and Palliative Medicine</i> , 2015, 32, 210-215.	0.8	13
31	The Preference of Place of Death and its Predictors Among Terminally Ill Patients With Cancer and Their Caregivers in China. <i>American Journal of Hospice and Palliative Medicine</i> , 2015, 32, 835-840.	0.8	36
32	Palliative sedation for terminally ill cancer patients in a tertiary cancer center in Shanghai, China. <i>BMC Palliative Care</i> , 2015, 14, 5.	0.8	21
33	Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. <i>Oncotarget</i> , 2015, 6, 2009-2022.	0.8	46
34	Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4559-4573.	3.2	59
35	The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-Dependent Autophagic, but Not Apoptotic Cell Death Pathway. <i>PLoS ONE</i> , 2014, 9, e85116.	1.1	39
36	Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e105524.	1.1	47

#	ARTICLE	IF	CITATIONS
37	Genetic polymorphism of the phospholipase C epsilon 1 gene and risk of gastric cancer. Chinese Medical Journal, 2014, 127, 2511-7.	0.9	9
38	The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. International Journal of Molecular Medicine, 2012, 30, 856-862.	1.8	57
39	Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration. Oncology Reports, 2012, 27, 1561-6.	1.2	10
40	High mobility group box 1 activates toll like receptor 4 signaling in hepatic stellate cells. Life Sciences, 2012, 91, 207-212.	2.0	27
41	Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Medicine, 2009, 7, 41.	2.3	127
42	Interval between Palliative Care Referral and Death among Patients Treated at a Comprehensive Cancer Center. Journal of Palliative Medicine, 2005, 8, 1025-1032.	0.6	144